AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29423713 — intervention group
Group type: COMPARATOR
Intervention: Negative control dentifrice (NC, fluoride-free)
Number of subjects: 62
Study 29423713 — intervention group
Group type: COMPARATOR
Intervention: Positive control dentifrice (PC)
Number of subjects: 62
Study 29423713 — intervention group
Group type: COMPARATOR
Intervention: Reference dentifrice (RD)
Number of subjects: 62
Study 29423713 — intervention group
Group type: COMPARATOR
Intervention: Negative control dentifrice (NC)
Number of subjects: 62
Study 27930531 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion (1 mg/kg bolus, 60 μg/kg/h continuous infusion)
Number of subjects: 58
Study 27930531 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline solution)
Number of subjects: 58
Study 27930531 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Ketamine and Control)
Number of subjects: 58
Study 24533878 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal ultrasound screening performed by trained health care staff
Number of subjects: 58
Study 24533878 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ultrasound screening)
Number of subjects: 58
Study 23342781 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Jianjing (GB 21)
Number of subjects: 60
Study 23342781 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture at non-acupoint
Number of subjects: 60
Study 20968198 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin (50 mL i.v. per day for 10 days)
Number of subjects: 100
Study 20968198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 18481933 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 Steps message
Number of subjects: 39
Study 18481933 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometers
Number of subjects: 39
Study 18481933 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) recommendations
Number of subjects: 39
Study 18481933 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking
Number of subjects: 39
Study 18481933 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) benefits
Number of subjects: 39
Study 18481933 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to PA
Number of subjects: 39
Study 18481933 — intervention group
Group type: EXPERIMENTAL
Intervention: Suggestions for promoting PA
Number of subjects: 39
Study 16013660 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal epidural anesthesia with prophylactic fluid loading (CSE-F)
Number of subjects: 30
Study 16013660 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal epidural anesthesia with prophylactic ephedrine (CSE-V)
Number of subjects: 30
Study 16013660 — intervention group
Group type: COMPARATOR
Intervention: Conventional epidural anesthesia with prophylactic fluid loading (EA-F)
Number of subjects: 30
Study 16013660 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal epidural anesthesia (CSE)
Number of subjects: 30
Study 16013660 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 30
Study 12208031 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminolaevulinic acid-induced photodynamic therapy (ALA-PDT)
Number of subjects: 26
Study 10713871 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam/remifentanil
Number of subjects: 60
Study 10713871 — intervention group
Group type: COMPARATOR
Intervention: propofol/fentanyl
Number of subjects: 60
Study 8737704 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival methylprednisolone hemisuccinate (MH) 40 mg in 0.5 cc
Number of subjects: 50
Study 8737704 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 50
Study 2187540 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (30 mg t.i.d.)
Number of subjects: 227
Study 2187540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study 6994782 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine (3-4 mg daily)
Number of subjects: 30
Study 6994782 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.3-0.45 mg daily)
Number of subjects: 30
Study 30264164 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus coagulans LBSC [2 billion/g]
Number of subjects: 60
Study 30264164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28095105 — intervention group
Group type: EXPERIMENTAL
Intervention: BAILAMOS© dance program
Number of subjects: 57
Study 28095105 — intervention group
Group type: COMPARATOR
Intervention: Health education program
Number of subjects: 57
Study 25832909 — intervention group
Group type: EXPERIMENTAL
Intervention: RPE-choroid graft transplantation surgery
Number of subjects: 20
Study 25832909 — intervention group
Group type: COMPARATOR
Intervention: Anti-VEGF treatment
Number of subjects: 20
Study 23358470 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg PO (days 1-21) and gemcitabine 1,000 mg/m² IV (days 1, 8, and 15) each 28-day cycle
Number of subjects: 72
Study 21316768 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term psychodynamic psychotherapy
Number of subjects: 367
Study 21316768 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term psychodynamic psychotherapy
Number of subjects: 367
Study 21316768 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoanalysis
Number of subjects: 367
Study 21316768 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution-focused therapy
Number of subjects: 367
Study 21316768 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term therapies
Number of subjects: 367
Study 21316768 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term therapy
Number of subjects: 367
Study 21316768 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 367
Study 19584651 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose recombinant tissue plasminogen activator (rt-PA) 50 mg with concomitant intravenous heparinization
Number of subjects: 52
Study 19584651 — intervention group
Group type: COMPARATOR
Intervention: Hemodilution
Number of subjects: 52
Study 17541702 — intervention group
Group type: EXPERIMENTAL
Intervention: Division of ilioinguinal nerve
Number of subjects: 172
Study 17541702 — intervention group
Group type: EXPERIMENTAL
Intervention: Division of genital nerve
Number of subjects: 172
Study 17541702 — intervention group
Group type: EXPERIMENTAL
Intervention: Division of iliohypogastric nerve
Number of subjects: 172
Study 17541702 — intervention group
Group type: COMPARATOR
Intervention: All three nerves preserved
Number of subjects: 172
Study 17541702 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant chronic pain cases
Number of subjects: 172
Study 15215801 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 5010
Study 15215801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5010
Study 11451842 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-Chamber Open Drainage System (TCOS)
Number of subjects: 224
Study 11451842 — intervention group
Group type: COMPARATOR
Intervention: Complex Closed Drainage System (CCDS)
Number of subjects: 224
Study 10078083 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg ibutilide
Number of subjects: 308
Study 10078083 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg ibutilide
Number of subjects: 308
Study 10078083 — intervention group
Group type: COMPARATOR
Intervention: 1.5 mg/kg DL-sotalol
Number of subjects: 308
Study 10078083 — intervention group
Group type: COMPARATOR
Intervention: DL-sotalol
Number of subjects: 308
Study 7978437 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 75 micrograms/h
Number of subjects: 32
Study 7978437 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 25 micrograms/h plus clonidine 0.3 micrograms.kg‐1.h‐1
Number of subjects: 32
Study 2514457 — intervention group
Group type: EXPERIMENTAL
Intervention: Two puffs of a mixture of 1 mg disodium cromoglycate and 0.5 mg of reproterol hydrochloride administered by metered dose inhaler through Volumatic spacer
Number of subjects: 18
Study 2514457 — intervention group
Group type: EXPERIMENTAL
Intervention: Two puffs of a mixture of 1 mg disodium cromoglycate and 0.5 mg of reproterol hydrochloride administered by metered dose inhaler through Nebuhaler spacer
Number of subjects: 18
Study 2514457 — intervention group
Group type: EXPERIMENTAL
Intervention: Two puffs of a mixture of 1 mg disodium cromoglycate and 0.5 mg of reproterol hydrochloride administered by metered dose inhaler through InspirEase spacer
Number of subjects: 18
Study 2514457 — intervention group
Group type: EXPERIMENTAL
Intervention: Two puffs of a mixture of 1 mg disodium cromoglycate and 0.5 mg of reproterol hydrochloride administered by metered dose inhaler through Synchron‐Aerosol spacer
Number of subjects: 18
Study 31009293 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual-Reality Endoscopy Trainer (VRET)
Number of subjects: 12
Study 31009293 — intervention group
Group type: COMPARATOR
Intervention: Live Dog Laboratory (LDL)
Number of subjects: 12
Study 30047216 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 1.0 mg
Number of subjects: 0
Study 30047216 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 0.25 mg
Number of subjects: 0
Study 30047216 — intervention group
Group type: COMPARATOR
Intervention: Liraglutide, Dulaglutide, Exenatide extended-release
Number of subjects: 0
Study 28329368 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily TMP-SMX plus monthly dihydroartemisinin-piperaquine (DP)
Number of subjects: 200
Study 28329368 — intervention group
Group type: COMPARATOR
Intervention: Daily TMP-SMX alone
Number of subjects: 200
Study 25946762 — intervention group
Group type: EXPERIMENTAL
Intervention: rilonacept
Number of subjects: 14
Study 25946762 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study 23404986 — intervention group
Group type: EXPERIMENTAL
Intervention: World Health Organization's Surgical Safety Checklist (SSC)
Number of subjects: 575
Study 23404986 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SSC implementation)
Number of subjects: 575
Study 21962313 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (≥ 5% and ≥ 20% body weight)
Number of subjects: 208
Study 21962313 — intervention group
Group type: COMPARATOR
Intervention: Weight gain
Number of subjects: 208
Study 21962313 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (≥ 20% body weight)
Number of subjects: 208
Study 21962313 — intervention group
Group type: COMPARATOR
Intervention: Weight change (stable or gained weight)
Number of subjects: 208
Study 21962313 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight management
Number of subjects: 208
Study 18253120 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin, paclitaxel, epirubicin (CEP)
Number of subjects: 208
Study 18253120 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin, paclitaxel, ifosfamide (CIP)
Number of subjects: 208
Study 16642422 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 1148
Study 16642422 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg
Number of subjects: 1148
Study 14520145 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 316
Study 10812310 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention at 16 weeks of gestation
Number of subjects: 123
Study 9275424 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic venous congestion syndrome (PVCSS) after tubal sterilization
Number of subjects: 21
Study 9275424 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal women after sterilization)
Number of subjects: 21
Study 9275424 — intervention group
Group type: EXPERIMENTAL
Intervention: Counts of macrophage in peritoneal fluid
Number of subjects: 21
Study 9275424 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma concentrations of ET‐1 and ANP
Number of subjects: 21
Study 2001781 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcard reminder
Number of subjects: 4
Study 2001781 — intervention group
Group type: COMPARATOR
Intervention: Control group (no postcard reminder)
Number of subjects: 4
Study 7201809 — intervention group
Group type: EXPERIMENTAL
Intervention: Niludipine (60 or 120 mg daily for five consecutive weeks, with an initial dose of 20 mg three times on the first day)
Number of subjects: 8
Study 7201809 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered for one week after the drug period)
Number of subjects: 8
Study 7201809 — intervention group
Group type: EXPERIMENTAL
Intervention: Niludipine (single dose study)
Number of subjects: 8
Study 30621689 — intervention group
Group type: EXPERIMENTAL
Intervention: Trigger system screening by trained nurses
Number of subjects: 100
Study 30621689 — intervention group
Group type: EXPERIMENTAL
Intervention: Trigger system screening
Number of subjects: 100
Study 27886564 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) at the top tertile
Number of subjects: 536
Study 27886564 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels
Number of subjects: 536
Study 25899566 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphenopalatine ganglion stimulation with one acupuncture needle for 4 weeks (once or twice weekly, total four to eight sessions)
Number of subjects: 96
Study 25899566 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphenopalatine ganglion stimulation with one acupuncture needle
Number of subjects: 96
Study 25899566 — intervention group
Group type: COMPARATOR
Intervention: Individualized verum acupuncture for 4 weeks (twice weekly, total eight sessions)
Number of subjects: 96
Study 25899566 — intervention group
Group type: COMPARATOR
Intervention: Individualized verum acupuncture
Number of subjects: 96
Study 24682026 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-expandable valve (Edwards Sapien XT)
Number of subjects: 241
Study 24682026 — intervention group
Group type: COMPARATOR
Intervention: Self-expandable valve (Medtronic CoreValve)
Number of subjects: 241
Study 23016126 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-exercise hyperhydration (PEH) with 26 mL/kg bodyweight of a 130 mmol/L sodium solution
Number of subjects: 6
Study 23016126 — intervention group
Group type: COMPARATOR
Intervention: Pre-exercise euhydration (PEE)
Number of subjects: 6
Study 23016126 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-exercise hyperhydration (PEH)
Number of subjects: 6
Study 19095343 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg micronised 17beta‐oestradiol plus 5 mg dydrogesterone (E/D group; n=18)
Number of subjects: 48
Study 19095343 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine oestrogens plus 5 mg medroxyprogesterone acetate (CEE/MPA group; n=14)
Number of subjects: 48
Study 19095343 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group; n=16)
Number of subjects: 48
Study 17292929 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber containing bar (alginate and guar gum)
Number of subjects: 0
Study 17292929 — intervention group
Group type: COMPARATOR
Intervention: Control bar
Number of subjects: 0
Study 15159225 — intervention group
Group type: EXPERIMENTAL
Intervention: Stearic acid diet
Number of subjects: 50
Study 15159225 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans fatty acids (TFA) diet
Number of subjects: 50
Study 15159225 — intervention group
Group type: EXPERIMENTAL
Intervention: TFA diet
Number of subjects: 50
Study 15159225 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleic acid diet
Number of subjects: 50
Study 11678959 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacy services (intervention group)
Number of subjects: 24
Study 11678959 — intervention group
Group type: COMPARATOR
Intervention: Routine clinic services (control group)
Number of subjects: 24
Study 9503255 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ipsapirone
Number of subjects: 80
Study 9503255 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg +/- pindolol
Number of subjects: 80
Study 9503255 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg +/- pindolol and 10 mg ipsapirone
Number of subjects: 80
Study 9503255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 7709763 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal salmon calcitonin (100 U on alternate days) + oral calcium (1500 mg daily)
Number of subjects: 47
Study 7709763 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated women)
Number of subjects: 47
Study 3108346 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (intracoronary streptokinase)
Number of subjects: 533
Study 3108346 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 533
Study 29605108 — intervention group
Group type: EXPERIMENTAL
Intervention: Video demonstration
Number of subjects: 74
Study 29605108 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone conversation with a radiographer
Number of subjects: 74
Study 29605108 — intervention group
Group type: COMPARATOR
Intervention: Routine MRI preparation (appointment letter)
Number of subjects: 74
Study 27780237 — intervention group
Group type: EXPERIMENTAL
Intervention: IPOS Neuro‐S8
Number of subjects: 134
Study 24326236 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS-DLPFC
Number of subjects: 18
Study 24326236 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 18
Study 22129475 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering treatment (Systolic BP≤140mmHg within 1 hour)
Number of subjects: 152
Study 22129475 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment strategy (target systolic BP of 180mmHg)
Number of subjects: 152
Study 19246136 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal yoga programme (12-14 weeks, 3 sessions per week, 30 minutes each)
Number of subjects: 88
Study 19246136 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal yoga programme
Number of subjects: 88
Study 19246136 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 88
Study 19098331 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass surgery
Number of subjects: 0
Study 19098331 — intervention group
Group type: COMPARATOR
Intervention: Conventional coronary artery bypass grafting
Number of subjects: 0
Study 14975534 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular pacing (cardiac resynchronisation therapy or CRT)
Number of subjects: 0
Study 14975534 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 11174538 — intervention group
Group type: COMPARATOR
Intervention: Composite resin control (Transbond XT)
Number of subjects: 160
Study 11174538 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin‐modified glass ionomer cement (Fuji Ortho LC)
Number of subjects: 160
Study 11174538 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyacid‐modified composite resin under dry conditions (Assure-dry)
Number of subjects: 160
Study 11174538 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyacid‐modified composite resin under wet conditions (Assure-wet)
Number of subjects: 160
Study 11174538 — intervention group
Group type: EXPERIMENTAL
Intervention: All adhesives
Number of subjects: 160
Study 11174538 — intervention group
Group type: EXPERIMENTAL
Intervention: Assure adhesive
Number of subjects: 160
Study 11174538 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample of extracted premolars
Number of subjects: 160
Study 11174538 — intervention group
Group type: EXPERIMENTAL
Intervention: Subset of sample (n = 34)
Number of subjects: 160
Study 9552068 — intervention group
Group type: EXPERIMENTAL
Intervention: 153Sm‐EDTMP 1.0 mCi/kg
Number of subjects: 118
Study 9552068 — intervention group
Group type: EXPERIMENTAL
Intervention: 153Sm‐EDTMP 0.5 mCi/kg
Number of subjects: 118
Study 9552068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 7919941 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol doses of 40-45 mg/day
Number of subjects: 60
Study 7919941 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol doses of 60-80 mg/day
Number of subjects: 60
Study 7919941 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol doses greater than 100 mg/day
Number of subjects: 60
Study 7919941 — intervention group
Group type: EXPERIMENTAL
Intervention: High haloperidol dosages
Number of subjects: 60
Study 3275486 — intervention group
Group type: EXPERIMENTAL
Intervention: vincristine, dactinomycin, and cyclophosphamide (VAC)
Number of subjects: 686
Study 3275486 — intervention group
Group type: COMPARATOR
Intervention: VAC + radiation
Number of subjects: 686
Study 3275486 — intervention group
Group type: EXPERIMENTAL
Intervention: vincristine and dactinomycin (VA) + radiation
Number of subjects: 686
Study 3275486 — intervention group
Group type: EXPERIMENTAL
Intervention: "pulse" VAC + radiation
Number of subjects: 686
Study 3275486 — intervention group
Group type: COMPARATOR
Intervention: "pulse" VAC + Adriamycin (doxorubicin) + radiation
Number of subjects: 686
Study 28832365 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment arm (SBP < 120 mmHg)
Number of subjects: 4732
Study 28832365 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment arm (SBP < 140 mmHg)
Number of subjects: 4732
Study 23567785 — intervention group
Group type: EXPERIMENTAL
Intervention: Subglottic and gastric treatment suspension (polymyxin E 100 mg, vancomycin 1 g, and amphotericin B 500 mg) + intravenous cefotaxime (1 g 3 times a day for 4 days)
Number of subjects: 44
Study 23567785 — intervention group
Group type: COMPARATOR
Intervention: Placebo + intravenous cefotaxime (1 g 3 times a day for 4 days)
Number of subjects: 44
Study 23567785 — intervention group
Group type: EXPERIMENTAL
Intervention: Subglottic placebo and gastric treatment suspension + intravenous cefotaxime (1 g 3 times a day for 4 days)
Number of subjects: 44
Study 23567785 — intervention group
Group type: EXPERIMENTAL
Intervention: Subglottic treatment suspension and gastric placebo + intravenous cefotaxime (1 g 3 times a day for 4 days)
Number of subjects: 44
Study 23481888 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated Tucking (FT)
Number of subjects: 20
Study 23481888 — intervention group
Group type: COMPARATOR
Intervention: No Facilitated Tucking (Control)
Number of subjects: 20
Study 20801180 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention for obese and overweight persons with anhedonia
Number of subjects: 82